Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-α in normal rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 285, Issue 6 54-6, 2003, Pages

  Francis, Joseph ^a   Beltz, Terry ^b   Johnson, Alan Kim ^b   Felder, Robert B ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b E11 SSH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Brain; Deoxycorticosterone acetate; Heart; Spironolactone

Indexed keywords

ALDOSTERONE; DEOXYCORTICOSTERONE ACETATE; MINERALOCORTICOID; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN REGION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEART; HYPOPHYSIS; HYPOTHALAMUS; MALE; NONHUMAN; PRIORITY JOURNAL; TISSUE; TISSUE DISTRIBUTION; TISSUE LEVEL;

EID: 0344420414     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00027.2003     Document Type: Article

References (49)

1. American Physiological Society. Guiding principles for research involving animals and human beings. Am J Physiol Regul Integr Comp Physiol 283: R281-R283, 2002.
2. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 25: 299-306, 2000.
3. Brilla CG and Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120: 893-901, 1992.
4. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80: 26L-40L, 1997.
5. Chrousos GP. The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann NY Acad Sci 917: 38-67, 2000.
6. Ciriello J. Contribution of forebrain mechanisms in the maintenance of deoxycorticosterone acetate-salt hypertension. Clin Exp Hypertens A 10, Suppl 1: 169-178, 1988.
7. Davidson J, Abul HT, Milton AS, and Rotondo D. Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain. Pflügers Arch 442: 526-533, 2001.
8. De Nicola AF, Grillo C, and Gonzalez S. Physiological, biochemical and molecular mechanisms of salt appetite control by mineralocorticoid action in brain. Braz J Med Biol Res 25: 1153-1162, 1992.
9. Dinarello CA, Cannon JG, Mancilla J, Bishai I, Lees J, and Coceani F. Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells. Brain Res 562: 199-206, 1991.
10. Duprez D, De Buyzere M, Rietzschel ER, and Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2: 327-334, 2000.
11. Felder RB, Francis J, Zhang ZH, Wei SG, Weiss RM, and Johnson AK. Heart failure and the brain: new perspectives. Am J Physiol Regul Integr Comp Physiol 284: R259-R276, 2003.
12. Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res 40: 97-105, 1999.
13. Francis J, Chu Y, Weiss RM, Johnson AK, and Felder RB. Hypothalamus: A novel site for the production of tumor necrosis factor-alpha after myocardial infarction in rats (Abstract). Circulation 106: 328, 2002.
14. Francis J, Wei SG, Weiss RM, Beltz T, Johnson AK, and Felder RB. Forebrain-mediated adaptations to myocardial infarction in the rat. Am J Physiol Heart Circ Physiol 282: H1898-H1906, 2002.
15. Francis J, Weiss RM, Johnson AK, and Felder RB. Central mineralocorticoid receptor blockade decreases plasma TNF-α after coronary artery ligation in rats. Am J Physiol Regul Integr Comp Physiol 284: R328-R335, 2003.
16. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, and Felder RB. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 281: H2241-H2251, 2001.
17. Francis J, Weiss RM, Wei SG, Johnson AK, and Felder RB. Progression of heart failure after myocardial infarction in the rat. Am J Physiol Regul Integr Comp Physiol 281: R1734-R1745, 2001.
18. Francis J, Zhang ZH, Weiss RM, and Felder RB. Differential regulation of heart, brain and circulating cytokines by the autonomic nervous system in rats with ischemia-induced heart failure (Abstract). Circulation In press.
19. Francis JS, Wei SG, Weiss RM, Johnson AK, and Felder RB. Central but not peripheral infusion of mineralocorticoid receptor antagonist decreases sympathetic drive early after coronary artery ligation in rats (Abstract). FASEB J 16: A791, 2002.
20. Fritsch Neves M and Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 5: 59-65, 2003.
21. Fujisawa G, Dilley R, Fullerton MJ, and Funder JW. Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 142: 3625-3631, 2001.
22. Funder JW. Aldosterone and mineralocorticoid receptors: orphan questions. Kidney Int 57: 1358-1363, 2000.
23. Gomez-Sanchez EP. Central hypertensive effects of aldosterone. Front Neuroendocrinol 18: 440-462, 1997.
24. Griendling KK and Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 91: 21-27, 2000.
25. Grillo CA, Saravia F, Ferrini M, Piroli G, Roig P, Garcia SI, de Kloet ER, and De Nicola AF. Increased expression of magnocellular vasopressin mRNA in rats with deoxycorticosterone-acetate induced salt appetite. Neuroendocrinology 68: 105-115, 1998.
26. Hilfenhaus M. Urinary aldosterone excretion rate and plasma aldosterone concentration in the rat: effect of ACTH, DOC, furosemide and of changes in sodium balance. Acta Endocrinol 85: 134-142, 1977.
27. Hoozemans JJ, Veerhuis R, Janssen I, Rozemuller AJ, and Eikelenboom P. Interleukin-1β induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp Gerontol 36: 559-570, 2001.
28. Hu S, Peterson PK, and Chao CC. Kappa-opioid modulation of human microglial cell superoxide anion generation. Biochem Pharmacol 56: 285-288, 1998.
29. Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen WH, Shou Z, and Liu P. Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation 99: 1492-1498, 1999.
30. Johnson AK, de Olmos J, Pastuskovas CV, Zardetto-Smith AM, and Vivas L. The extended amygdala and salt appetite. Ann NY Acad Sci 877: 258-280, 1999.
31. Li YF and Patel KP. Paraventricular nucleus of the hypothalamus and elevated sympathetic activity in heart failure: the altered inhibitory mechanisms. Acta Physiol Scand 177: 17-26, 2003.
32. Lijnen P and Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 32: 865-879, 2000.
33. Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC, and Feuerstein GZ. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 25: 1481-1488, 1994.
34. Malmqvist K, Ohman KP, Lind L, Nystrom F, and Kahan T. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 252: 430-439, 2002.
35. McEwen BS, Lambdin LT, Rainbow TC, and De Nicola AF. Aldosterone effects on salt appetite in adrenalectomized rats. Neuroendocrinology 43: 38-43, 1986.
36. Murray DR, Prabhu SD, and Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 101: 2338-2341, 2000.
37. Nakamura T, Ebihara I, Fukui M, Takahashi T, Tomino Y, and Koide H. Altered glomerular steady-state levels of tumour necrosis factor-α MRNA during nephrotic and sclerotic phases of puromycin aminonucleoside nephrosis in rats. Clin Sci (Lond) 84: 349-356, 1993.
38. Nakata T, Takeda K, Itho H, Hirata M, Kawasaki S, Hayashi J, Oguro M, Sasaki S, and Nakagawa M. Paraventricular nucleus lesions attenuate the development of hypertension in DOCA/salt-treated rats. Am J Hypertens 2: 625-630, 1989.
39. Reichlin S. Alternative pathways of neural control of the immune process. Ann NY Acad Sci 840: 301-316, 1998.
40. Rodriguez-Sargent C, Torres-Negron I, Cangiano JL, and Martinez-Maldonado M. Deoxycorticosterone hypertension in the intact weanling rat without salt loading. Hypertension 15: I112-I116, 1990.
41. Saravia FE, Grillo CA, Ferrini M, Roig P, Lima AE, de Kloet ER, and De Nicola AF. Changes of hypothalamic and plasma vasopressin in rats with deoxycorticosterone-acetate induced salt appetite. J Steroid Biochem Mol Biol 70: 47-57, 1999.
42. Stier CT Jr, Chander PN, and Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10: 97-107, 2002.
43. Turnbull AV, Lee S, and Rivier C. Mechanisms of hypothalamic-pituitary-adrenal axis stimulation by immune signals in the adult rat. Ann NY Acad Sci 840: 434-443, 1998.
44. Weber KT, Sun Y, Campbell SE, Slight SH, Ganjam VK, Griffing GT, Swinfard RW, and Diaz-Arias AA. Chronic mineralocorticoid excess and cardiovascular remodeling. Steroids 60: 125-132, 1995.
45. Weiss ML, Kenney MJ, Musch TI, and Patel KP. Modifications to central neural circuitry during heart failure. Acta Physiol Scand 177: 57-67, 2003.
46. Zhang DM, Epstein AN, and Schulkin J. Medial region of the amygdala: involvement in adrenal-steroid-induced salt appetite. Brain Res 600: 20-26, 1993.
47. Zhang ZH, Wei SG, Francis J, and Felder RB. Cardiovascular and renal sympathetic activation by blood-borne TNF-α in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 284: R916-R927, 2003.
48. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, and Davisson RL. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 91: 1038-1045, 2002.
49. Zucker IH, Wang W, Pliquett RU, Liu JL, and Patel KP. The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann NY Acad Sci 940: 431-443, 2001.